Mersana Therapeutics to Present at World ADC San Diego
CAMBRIDGE, Mass., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. today announced its presentation at World ADC San Diego, taking place October 19-22, 2015, at the Sheraton San Diego Hotel & Marina.
The presentation details are as follows:
Date: Wednesday, October 21, 2015
Time: 3:30 p.m. PT
Title: Fleximer ADCs: Advancing the Platforms Towards the Clinic
Conference Section: Pioneering New Developments to Fuel the ADCs of the Future
Presenter: Timothy Lowinger, Ph.D., Chief Scientific Officer, Mersana Therapeutics
World ADC San Diego provides a forum for sharing new antibody drug conjugate insights and data. For more information about the event, visit http://worldadc-usa.com/.
About Mersana Therapeutics
Mersana Therapeutics is advancing a proprietary pipeline of targeted oncology therapeutics leveraging its game-changing Fleximer® immunoconjugate technology. Mersana's first product candidate XMT-1522 has the potential to address significant unmet needs and improve patient outcomes in multiple oncology indications. Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously considered not amenable to antibody-drug conjugate approaches. Mersana has collaborations utilizing Fleximer technology with Takeda, Merck KGaA, and Asana BioSciences. For more information, please visit www.mersana.com.
CONTACT: Media Contact
6 Degrees
Tony Plohoros
tplohoros@6degreespr.com
(908) 591-2839
Investors Contact
Stern Investor Relations, Inc.
Jesse Baumgartner
Jesse@sternir.com
(212) 362-1200
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
